Banzel Mobile Logo A Challenging Form of Epilepsy Seizure Types in LGS LGS Patient Profiles Pivotal Trial Design Efficacy of BANZEL® in Seizure Reduction Seizure Severity Rating Responder Rates Adverse Reactions Mechanism of Action/Pharmacokinetics Dosing

BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.

Prescribing Information Important Safety Information For Patients

MECHANISM OF ACTION (MOA) / PHARMACOKINETICS

BANZEL® (rufinamide) is a triazole derivative structurally unrelated to currently available AEDs1

  • Clinical significance has not been established
  • The precise mechanism(s) of action of BANZEL is unknown. It is thought to prolong the inactive state of sodium channels1

Pharmacokinetics

  • Metabolic route is not cytochrome P450-dependent: metabolized by carboxylesterases1
  • Well absorbed orally with a tmax of 4-6 hours1
    • However, the rate of absorption is relatively slow and extent of absorption is decreased as dose is increased
  • Steady state is reached within 2 days2
  • Plasma elimination half-life (t1/2) is approximately 6-10 hours1
  • Low protein binding (approximately 34%)1
  • The pharmacokinetics of BANZEL in the pediatric population (age 1-17 years) is similar to that in adults1
  • References: 1. BANZEL® (rufinamide) prescribing information, Eisai Inc. 2. Perucca et al. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49(7):1123-1141.
◄ Previous Next: DOSING►
Efficacy icon

EFFICACY ►

Learn about the efficacy of BANZEL® (rufinamide) in the pivotal trial